Baaboon的个人主页 - 老虎社区

Baaboon

暂无个人介绍

IP属地：未知

2关注

0粉丝

0主题

0勋章

2021-12-08

Meme your mother

Meme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote>

2021-12-07

I am betting on your mother

Ocugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote>

2021-10-21

Mother fool

7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote>

2021-04-23

Retarded face

抱歉，原内容已删除

2021-04-21

Please talk about Ocugen OCGN. They will be saving the world, together with India.

Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577579226988656","uuid":"3577579226988656","gmtCreate":1614485203854,"gmtModify":1614485203854,"name":"Baaboon","pinyin":"baaboon","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":602333381,"gmtCreate":1638969966940,"gmtModify":1638969966940,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577579226988656","idStr":"3577579226988656"},"themes":[],"htmlText":"Meme your mother&nbsp;","listText":"Meme your mother&nbsp;","text":"Meme your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602333381","repostId":"1160989369","repostType":2,"repost":{"id":"1160989369","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890853,"share":"https://www.laohu8.com/m/news/1160989369?lang=zh_CN&edition=full","pubTime":"2021-12-07 23:27","market":"us","language":"en","title":"Meme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160989369","media":"Tiger Newspress","summary":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisit","content":"<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p><p><blockquote>Meme股票在早盘交易中上涨。Vinco Ventures、IronNet、Zomedica、Aterian、Digital World Acquisition、Greenidge Generation、Senseonics、Newegg、AMC和游戏驿站上涨5%至18%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-07 23:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p><p><blockquote>Meme股票在早盘交易中上涨。Vinco Ventures、IronNet、Zomedica、Aterian、Digital World Acquisition、Greenidge Generation、Senseonics、Newegg、AMC和游戏驿站上涨5%至18%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KOSS":"高斯电子","BBIG":"Vinco Ventures, Inc.","EXPR":"Express, Inc.","CLOV":"Clover Health Corp","GREE":"Greenidge Generation Holdings Inc.","OCGN":"Ocugen","GME":"游戏驿站","ATER":"Aterian Inc.","NEGG":"Newegg Comm Inc.","BB":"黑莓","AMC":"AMC院线","BBBY":"Bed Bath & Beyond, Inc.","PHUN":"Phunware, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160989369","content_text":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC and GameStop climbed between 5% and 18%.","news_type":1,"symbols_score_info":{"BB":0.9,"CLOV":0.9,"DWAC":0.9,"EXPR":0.9,"BBBY":0.9,"ATER":0.9,"GREE":0.9,"ZOM":0.9,"MRIN":0.9,"PHUN":0.9,"IRNT":0.9,"AMC":0.9,"NEGG":0.9,"KOSS":0.9,"GME":0.9,"OCGN":0.9,"BBIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606614244,"gmtCreate":1638870615594,"gmtModify":1638870615594,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577579226988656","idStr":"3577579226988656"},"themes":[],"htmlText":"I am betting on&nbsp;your mother","listText":"I am betting on&nbsp;your mother","text":"I am betting on your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606614244","repostId":"1159607563","repostType":2,"repost":{"id":"1159607563","kind":"news","pubTimestamp":1638861435,"share":"https://www.laohu8.com/m/news/1159607563?lang=zh_CN&edition=full","pubTime":"2021-12-07 15:17","market":"us","language":"en","title":"Ocugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159607563","media":"InvestorPlace","summary":"Don't go bottom-fishing with OCGN stock even if it's at an enticing support level","content":"<p><div> For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price. Yet, let’s not forget the...</p><p><blockquote><div>对于技术交易者来说，积累生物制药公司Ocugen（纳斯达克股票代码：OCGN）的股票可能很有诱惑力，因为OCGN股票已经跌至看似公平的价格。然而，我们不要忘记...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-07 15:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price. Yet, let’s not forget the...</p><p><blockquote><div>对于技术交易者来说，积累生物制药公司Ocugen（纳斯达克股票代码：OCGN）的股票可能很有诱惑力，因为OCGN股票已经跌至看似公平的价格。然而，我们不要忘记...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159607563","content_text":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is known as Covaxin.\nOcugen is co-developing Covaxin with India-based Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring 2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853539585,"gmtCreate":1634823296736,"gmtModify":1634823712607,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577579226988656","idStr":"3577579226988656"},"themes":[],"htmlText":"Mother fool","listText":"Mother fool","text":"Mother fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853539585","repostId":"1171915283","repostType":2,"repost":{"id":"1171915283","kind":"news","pubTimestamp":1634817585,"share":"https://www.laohu8.com/m/news/1171915283?lang=zh_CN&edition=full","pubTime":"2021-10-21 19:59","market":"us","language":"en","title":"7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171915283","media":"Motley Fool","summary":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so f","content":"<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p><p><blockquote>股票表现之间不存在竞争<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）今年迄今为止。Ocugen的股价飙升约为Novavax的七倍。</blockquote></p><p> Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p><p><blockquote>这是否使Ocugen成为现在购买更明智的疫苗股票？一点也不。以下是Novavax股票比Ocugen更容易选择的七个原因。</blockquote></p><p> 1. A path to EUA in the U.S.</p><p><blockquote>1.美国EUA之路。</blockquote></p><p> Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p><p><blockquote>Ocugen的股价在2021年两次飙升超过750%。但在该公司6月份披露将不再在美国寻求COVID-19疫苗科瓦克辛的紧急使用授权(EUA)后，这一巨大收益大部分消失了。</blockquote></p><p> The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p><p><blockquote>该公司选择在美国获得全面批准后立即获得批准。美国食品药品监督管理局限制了哪些疫苗将在EUA计划下接受审查。然而，到目前为止，Ocugen尚未开始获得FDA全面批准所需的后期临床研究。</blockquote></p><p> Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p><p><blockquote>与此同时，Novavax仍将其COVID-19候选疫苗NVX-CoV2373的美国EUA作为重中之重。该公司在美国申请授权的时间将比预期的要晚。然而，它有可能比Ocugen更早在美国推出。</blockquote></p><p> Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p><p><blockquote>Ocugen仍希望获得科瓦克辛在加授权。但美国是大奖。Novavax现在显然有更好的机会获得这个奖项。</blockquote></p><p> 2. Supply deals already in hand</p><p><blockquote>2.已在手的供应交易</blockquote></p><p> Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p><p><blockquote>一些投资者完全关注COVID-19疫苗的批准或授权流程。然而，如果没有与至少一个国家达成供应协议，任何监管上的胜利都将是空洞的胜利。</blockquote></p><p> Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p><p><blockquote>Ocugen尚未敲定任何供应交易。另一方面，Novavax已经与美国、加拿大、欧盟、澳大利亚、新西兰、日本（通过其合作伙伴，<b>武田</b>）和疫苗联盟Gavi。</blockquote></p><p> 3. Full rights to its COVID-19 vaccine</p><p><blockquote>3.对其COVID-19疫苗的完全权利</blockquote></p><p> Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p><p><blockquote>Ocugen仅在美国和加拿大从Bharat Biotech获得了科瓦克辛的商业化权利。它与Bharat的条款允许该公司保留在这两个市场销售COVID-19疫苗利润的45%。</blockquote></p><p> Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p><p><blockquote>Novavax自行开发了NVX-CoV2373。它保留了疫苗的全部权利，尽管它已经与其他组织合作瞄准了一些市场。</blockquote></p><p> 4. A stronger pipeline</p><p><blockquote>4.更强大的管道</blockquote></p><p> Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p><p><blockquote>除了科瓦克辛之外，Ocugen目前没有任何其他正在进行临床测试的候选产品。该公司曾表示，计划在2021年将实验性基因疗法OCU400推进到两项1/2a期临床试验中，但这些研究尚未开始。</blockquote></p><p> Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p><p><blockquote>Novavax已经报告了候选流感疫苗NanoFlu的3期研究的积极结果。它于9月启动了一项1/2期研究，评估NVX-CoV2373和NanoFlu的组合。该公司还有另外两种处于临床阶段的候选疫苗——呼吸道合胞病毒疫苗ResVax和埃博拉病毒疫苗。</blockquote></p><p> 5. More cash</p><p><blockquote>5.更多现金</blockquote></p><p> Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p><p><blockquote>现金对于临床阶段的生物技术极其重要。如果没有足够的现金，他们可能被迫通过稀释性股票发行来筹集资金，为运营和昂贵的临床试验提供资金。</blockquote></p><p> As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p><p><blockquote>截至2021年6月30日，Ocugen的现金、现金等价物和限制性现金总计1.158亿美元。截至同日，Novavax的现金储备为21亿美元。</blockquote></p><p> 6. More potential near-term catalysts</p><p><blockquote>6.更多潜在的近期催化剂</blockquote></p><p> Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p><p><blockquote>Ocugen实际上只有一个可靠的潜在近期催化剂：它正在等待加拿大卫生部关于科瓦克辛授权的决定。该疫苗在加拿大或美国以外的任何胜利都有利于Bharat，但不利于Ocugen。</blockquote></p><p> What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p><p><blockquote>诺瓦瓦克斯呢？该公司希望尽快赢得印度、印度尼西亚和菲律宾的EUA。Novavax正在等待世界卫生组织将NVX-CoV2373列入紧急使用清单。它还正在向英国、欧洲、澳大利亚、加拿大、新西兰和美国提交监管文件。</blockquote></p><p> 7. A more defensible valuation</p><p><blockquote>7.更合理的估值</blockquote></p><p> Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p><p><blockquote>Ocugen今年迄今为止令人印象深刻的表现在很大程度上源于强烈的在线兴趣和大量股票被卖空的结合。这使得该股成为空头挤压的良好候选者。但该公司的市值超过16亿美元，分析师预计Ocugen明年的收入仅为1.35亿美元左右。</blockquote></p><p> Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p><p><blockquote>不过，如果Novavax获得NVX-CoV2373的授权和批准，它可能很快就会看到大笔资金流入。该公司的市值接近124亿美元。然而，由于预计2022年收入为55亿美元，这一估值比Ocugen的估值更合理。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-21 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p><p><blockquote>股票表现之间不存在竞争<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）今年迄今为止。Ocugen的股价飙升约为Novavax的七倍。</blockquote></p><p> Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p><p><blockquote>这是否使Ocugen成为现在购买更明智的疫苗股票？一点也不。以下是Novavax股票比Ocugen更容易选择的七个原因。</blockquote></p><p> 1. A path to EUA in the U.S.</p><p><blockquote>1.美国EUA之路。</blockquote></p><p> Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p><p><blockquote>Ocugen的股价在2021年两次飙升超过750%。但在该公司6月份披露将不再在美国寻求COVID-19疫苗科瓦克辛的紧急使用授权(EUA)后，这一巨大收益大部分消失了。</blockquote></p><p> The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p><p><blockquote>该公司选择在美国获得全面批准后立即获得批准。美国食品药品监督管理局限制了哪些疫苗将在EUA计划下接受审查。然而，到目前为止，Ocugen尚未开始获得FDA全面批准所需的后期临床研究。</blockquote></p><p> Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p><p><blockquote>与此同时，Novavax仍将其COVID-19候选疫苗NVX-CoV2373的美国EUA作为重中之重。该公司在美国申请授权的时间将比预期的要晚。然而，它有可能比Ocugen更早在美国推出。</blockquote></p><p> Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p><p><blockquote>Ocugen仍希望获得科瓦克辛在加授权。但美国是大奖。Novavax现在显然有更好的机会获得这个奖项。</blockquote></p><p> 2. Supply deals already in hand</p><p><blockquote>2.已在手的供应交易</blockquote></p><p> Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p><p><blockquote>一些投资者完全关注COVID-19疫苗的批准或授权流程。然而，如果没有与至少一个国家达成供应协议，任何监管上的胜利都将是空洞的胜利。</blockquote></p><p> Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p><p><blockquote>Ocugen尚未敲定任何供应交易。另一方面，Novavax已经与美国、加拿大、欧盟、澳大利亚、新西兰、日本（通过其合作伙伴，<b>武田</b>）和疫苗联盟Gavi。</blockquote></p><p> 3. Full rights to its COVID-19 vaccine</p><p><blockquote>3.对其COVID-19疫苗的完全权利</blockquote></p><p> Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p><p><blockquote>Ocugen仅在美国和加拿大从Bharat Biotech获得了科瓦克辛的商业化权利。它与Bharat的条款允许该公司保留在这两个市场销售COVID-19疫苗利润的45%。</blockquote></p><p> Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p><p><blockquote>Novavax自行开发了NVX-CoV2373。它保留了疫苗的全部权利，尽管它已经与其他组织合作瞄准了一些市场。</blockquote></p><p> 4. A stronger pipeline</p><p><blockquote>4.更强大的管道</blockquote></p><p> Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p><p><blockquote>除了科瓦克辛之外，Ocugen目前没有任何其他正在进行临床测试的候选产品。该公司曾表示，计划在2021年将实验性基因疗法OCU400推进到两项1/2a期临床试验中，但这些研究尚未开始。</blockquote></p><p> Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p><p><blockquote>Novavax已经报告了候选流感疫苗NanoFlu的3期研究的积极结果。它于9月启动了一项1/2期研究，评估NVX-CoV2373和NanoFlu的组合。该公司还有另外两种处于临床阶段的候选疫苗——呼吸道合胞病毒疫苗ResVax和埃博拉病毒疫苗。</blockquote></p><p> 5. More cash</p><p><blockquote>5.更多现金</blockquote></p><p> Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p><p><blockquote>现金对于临床阶段的生物技术极其重要。如果没有足够的现金，他们可能被迫通过稀释性股票发行来筹集资金，为运营和昂贵的临床试验提供资金。</blockquote></p><p> As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p><p><blockquote>截至2021年6月30日，Ocugen的现金、现金等价物和限制性现金总计1.158亿美元。截至同日，Novavax的现金储备为21亿美元。</blockquote></p><p> 6. More potential near-term catalysts</p><p><blockquote>6.更多潜在的近期催化剂</blockquote></p><p> Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p><p><blockquote>Ocugen实际上只有一个可靠的潜在近期催化剂：它正在等待加拿大卫生部关于科瓦克辛授权的决定。该疫苗在加拿大或美国以外的任何胜利都有利于Bharat，但不利于Ocugen。</blockquote></p><p> What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p><p><blockquote>诺瓦瓦克斯呢？该公司希望尽快赢得印度、印度尼西亚和菲律宾的EUA。Novavax正在等待世界卫生组织将NVX-CoV2373列入紧急使用清单。它还正在向英国、欧洲、澳大利亚、加拿大、新西兰和美国提交监管文件。</blockquote></p><p> 7. A more defensible valuation</p><p><blockquote>7.更合理的估值</blockquote></p><p> Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p><p><blockquote>Ocugen今年迄今为止令人印象深刻的表现在很大程度上源于强烈的在线兴趣和大量股票被卖空的结合。这使得该股成为空头挤压的良好候选者。但该公司的市值超过16亿美元，分析师预计Ocugen明年的收入仅为1.35亿美元左右。</blockquote></p><p> Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p><p><blockquote>不过，如果Novavax获得NVX-CoV2373的授权和批准，它可能很快就会看到大笔资金流入。该公司的市值接近124亿美元。然而，由于预计2022年收入为55亿美元，这一估值比Ocugen的估值更合理。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171915283","content_text":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes that make Ocugen the smarter vaccine stock to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.\n1. A path to EUA in the U.S.\nOcugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.\nThe company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.\nMeanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.\nOcugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.\n2. Supply deals already in hand\nSome investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.\nOcugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,Takeda), and Gavi, the Vaccine Alliance.\n3. Full rights to its COVID-19 vaccine\nOcugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.\nNovavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.\n4. A stronger pipeline\nOther than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.\nNovavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.\n5. More cash\nCash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.\nAs of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.\n6. More potential near-term catalysts\nOcugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.\nWhat about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.\n7. A more defensible valuation\nOcugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.\nNovavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.","news_type":1,"symbols_score_info":{"OCGN":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":372941567,"gmtCreate":1619171841559,"gmtModify":1634288015707,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577579226988656","idStr":"3577579226988656"},"themes":[],"htmlText":"Retarded&nbsp;face","listText":"Retarded&nbsp;face","text":"Retarded face","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/372941567","repostId":"1144940040","repostType":4,"isVote":1,"tweetType":1,"viewCount":1633,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378192346,"gmtCreate":1619008614285,"gmtModify":1634289268600,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577579226988656","idStr":"3577579226988656"},"themes":[],"htmlText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","listText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","text":"Please talk about Ocugen OCGN. They will be saving the world, together with India.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/378192346","repostId":"1133987686","repostType":4,"repost":{"id":"1133987686","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619007348,"share":"https://www.laohu8.com/m/news/1133987686?lang=zh_CN&edition=full","pubTime":"2021-04-21 20:15","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133987686","media":"Tiger Newspress","summary":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. fu","content":"<p><ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p><blockquote><ul><li>Netflix拖累纳斯达克期货</li></ul><ul><li>10年期国债收益率跌至5周低点后停止涨势</li></ul>美国期货涨跌互现，因为纳斯达克100指数表现不佳，表明从大流行热门股的轮换正在取得进展。美国国债收益率止住了跌至五周低点的下滑。</blockquote></p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨11点，涨幅0.03%，标普500 e-mini下跌0.75点，涨幅0.02%，纳斯达克100 e-mini下跌26.75点，涨幅0.19%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:00</span></p></blockquote></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><blockquote>流媒体服务提供商Netflix在盘前交易中下跌8.5%，此前其报告显示，疫情期间电视节目和电影制作放缓损害了第一季度的订户增长。</blockquote></p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><blockquote><b>Netflix(NFLX)</b>–Netflix在盘前交易中下跌8.5%，尽管其最新季度的营收和利润均超出预期。投资者关注这家视频流媒体巨头弱于预期的用户增长数据。</blockquote></p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><blockquote><b>阿斯麦(ASML)</b>–ASML公布第一季度利润好于预期，该半导体制造设备供应商受益于全球芯片需求激增，盘前股价上涨3.9%。ASML也上调了全年预期。</blockquote></p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><blockquote><b>现代（MRNA）</b>–在与以色列达成2022年新的Covid-19疫苗供应协议后，该制药商股价在盘前交易中上涨0.5%。以色列还可以选择购买旨在治疗特定病毒变种的疫苗。</blockquote></p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><blockquote><b>挪威邮轮公司(NCLH)</b>-高盛将这家邮轮运营商的评级从“中性”上调至“买入”后，挪威股价盘前上涨1.8%。高盛列举了几个积极因素，包括挪威航空的产能增长和与同行相比的低杠杆率。</blockquote></p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><blockquote><b>威瑞森(VZ)</b>-Verizon公布季度收益为每股1.31美元，比预期高出2美分。收入也超出了分析师的预期。Verizon本季度失去的无线用户数量超出了分析师的预期。</blockquote></p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><blockquote><b>韦尔比尔特(WBT)</b>-专业餐饮服务设备制造商Welbilt同意被竞争对手Middleby(MIDD)以隐含价值43亿美元的全股票交易收购，该公司股价在盘前飙升20%。</blockquote></p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><blockquote><b>国歌(ANTM)</b>-这家健康保险公司最近一个季度每股收益7.01美元，比预期高出50美分。收入低于华尔街的预测。由于各种医疗计划的增长和药房福利管理收入的增加，Anthem还上调了全年预期。该股在盘前交易中上涨1.6%。</blockquote></p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><blockquote><b>纳斯达克(NDAQ)</b>–该证券交易所运营商第一季度每股收益1.96美元，比预期高出23美分。收入也高于华尔街的预测。股票和固定收益交易收入两位数增长提振了业绩。纳斯达克还宣布将股息增加10%。</blockquote></p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><blockquote><b>哈里伯顿(HAL)</b>-哈里伯顿股价在盘前上涨1.7%，每股收益超出预期2美分，季度利润为每股19美分。收入也高于预期，这家油田服务公司表示其北美业务继续健康复苏。</blockquote></p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><blockquote><b>贝克休斯(BKR)</b>–这家油田服务公司公布季度收益为每股12美分，比预期高出每股1美分，盘前股价下跌1.4%。收入基本符合预期。受严冬天气影响，利润同比下降40%。</blockquote></p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><blockquote><b>CSX(CSX)</b>-CSX每股下跌2美分，低于预期，季度收益为每股93美分。该铁路运营商的收入高于预期。与大流行相关的中断和更高的燃料成本侵蚀了CSX的利润。CSX在盘前交易中下跌1%。</blockquote></p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><blockquote><b>直觉外科(ISRG)</b>-Intuitive Surgical最近一个季度的每股收益为3.52美元，远高于每股2.63美元的普遍预期。这家手术设备制造商的收入也超出了预期，随着Covid-19大流行的缓解，使用该公司设备的手术数量有所增加。该股在盘前交易中上涨3.9%。</blockquote></p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><blockquote><b>特尼特医疗保健(THC)</b>-Tenet报告季度利润为每股1.30美元，而市场普遍预期为每股72美分。医院运营商的收入略高于预期。特尼特表示，它能够成功应对与大流行和冬季风暴相关的挑战，并给出了乐观的前景。Tenet在盘前交易中上涨2.7%。</blockquote></p><p></p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><blockquote><b>盈透证券(IBKR)</b>-盈透证券每股收益比预期高出7美分，季度收益为每股98美分。交易佣金增长53%，收入远高于预期。该股在盘前交易中上涨2.1%。</blockquote></p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p><p><blockquote><b>爱德华兹生命科学(EW)</b>-爱德华兹股价盘前上涨3.8%，每股收益超出预期7美分，季度利润为每股54美分。收入也高于普遍预期，由于心脏相关手术需求的预期增加，该医疗器械公司还上调了全年预期。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-21 20:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p><blockquote><ul><li>Netflix拖累纳斯达克期货</li></ul><ul><li>10年期国债收益率跌至5周低点后停止涨势</li></ul>美国期货涨跌互现，因为纳斯达克100指数表现不佳，表明从大流行热门股的轮换正在取得进展。美国国债收益率止住了跌至五周低点的下滑。</blockquote></p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨11点，涨幅0.03%，标普500 e-mini下跌0.75点，涨幅0.02%，纳斯达克100 e-mini下跌26.75点，涨幅0.19%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:00</span></p></blockquote></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><blockquote>流媒体服务提供商Netflix在盘前交易中下跌8.5%，此前其报告显示，疫情期间电视节目和电影制作放缓损害了第一季度的订户增长。</blockquote></p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><blockquote><b>Netflix(NFLX)</b>–Netflix在盘前交易中下跌8.5%，尽管其最新季度的营收和利润均超出预期。投资者关注这家视频流媒体巨头弱于预期的用户增长数据。</blockquote></p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><blockquote><b>阿斯麦(ASML)</b>–ASML公布第一季度利润好于预期，该半导体制造设备供应商受益于全球芯片需求激增，盘前股价上涨3.9%。ASML也上调了全年预期。</blockquote></p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><blockquote><b>现代（MRNA）</b>–在与以色列达成2022年新的Covid-19疫苗供应协议后，该制药商股价在盘前交易中上涨0.5%。以色列还可以选择购买旨在治疗特定病毒变种的疫苗。</blockquote></p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><blockquote><b>挪威邮轮公司(NCLH)</b>-高盛将这家邮轮运营商的评级从“中性”上调至“买入”后，挪威股价盘前上涨1.8%。高盛列举了几个积极因素，包括挪威航空的产能增长和与同行相比的低杠杆率。</blockquote></p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><blockquote><b>威瑞森(VZ)</b>-Verizon公布季度收益为每股1.31美元，比预期高出2美分。收入也超出了分析师的预期。Verizon本季度失去的无线用户数量超出了分析师的预期。</blockquote></p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><blockquote><b>韦尔比尔特(WBT)</b>-专业餐饮服务设备制造商Welbilt同意被竞争对手Middleby(MIDD)以隐含价值43亿美元的全股票交易收购，该公司股价在盘前飙升20%。</blockquote></p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><blockquote><b>国歌(ANTM)</b>-这家健康保险公司最近一个季度每股收益7.01美元，比预期高出50美分。收入低于华尔街的预测。由于各种医疗计划的增长和药房福利管理收入的增加，Anthem还上调了全年预期。该股在盘前交易中上涨1.6%。</blockquote></p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><blockquote><b>纳斯达克(NDAQ)</b>–该证券交易所运营商第一季度每股收益1.96美元，比预期高出23美分。收入也高于华尔街的预测。股票和固定收益交易收入两位数增长提振了业绩。纳斯达克还宣布将股息增加10%。</blockquote></p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><blockquote><b>哈里伯顿(HAL)</b>-哈里伯顿股价在盘前上涨1.7%，每股收益超出预期2美分，季度利润为每股19美分。收入也高于预期，这家油田服务公司表示其北美业务继续健康复苏。</blockquote></p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><blockquote><b>贝克休斯(BKR)</b>–这家油田服务公司公布季度收益为每股12美分，比预期高出每股1美分，盘前股价下跌1.4%。收入基本符合预期。受严冬天气影响，利润同比下降40%。</blockquote></p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><blockquote><b>CSX(CSX)</b>-CSX每股下跌2美分，低于预期，季度收益为每股93美分。该铁路运营商的收入高于预期。与大流行相关的中断和更高的燃料成本侵蚀了CSX的利润。CSX在盘前交易中下跌1%。</blockquote></p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><blockquote><b>直觉外科(ISRG)</b>-Intuitive Surgical最近一个季度的每股收益为3.52美元，远高于每股2.63美元的普遍预期。这家手术设备制造商的收入也超出了预期，随着Covid-19大流行的缓解，使用该公司设备的手术数量有所增加。该股在盘前交易中上涨3.9%。</blockquote></p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><blockquote><b>特尼特医疗保健(THC)</b>-Tenet报告季度利润为每股1.30美元，而市场普遍预期为每股72美分。医院运营商的收入略高于预期。特尼特表示，它能够成功应对与大流行和冬季风暴相关的挑战，并给出了乐观的前景。Tenet在盘前交易中上涨2.7%。</blockquote></p><p></p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><blockquote><b>盈透证券(IBKR)</b>-盈透证券每股收益比预期高出7美分，季度收益为每股98美分。交易佣金增长53%，收入远高于预期。该股在盘前交易中上涨2.1%。</blockquote></p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p><p><blockquote><b>爱德华兹生命科学(EW)</b>-爱德华兹股价盘前上涨3.8%，每股收益超出预期7美分，季度利润为每股54美分。收入也高于普遍预期，由于心脏相关手术需求的预期增加，该医疗器械公司还上调了全年预期。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NCLH":"挪威邮轮","HAL":"哈里伯顿","NFLX":"奈飞","THC":"泰尼特",".IXIC":"NASDAQ Composite","VZ":"Verizon Comms",".SPX":"S&P 500 Index","WBT":" Manitowoc Food Service",".DJI":"道琼斯","MRNA":"Moderna, Inc.","ASML":"阿斯麦","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133987686","content_text":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.*Source From Tiger Trade, EST 08:00Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.Stocks making the biggest moves in the premarket:Netflix (NFLX) – Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.ASML (ASML) – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.Moderna (MRNA) – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.Norwegian Cruise Line (NCLH) – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.Verizon (VZ) – Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.Welbilt (WBT) – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.Anthem (ANTM) – The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.Nasdaq (NDAQ) – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.Halliburton (HAL) – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.Baker Hughes (BKR) – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.CSX (CSX) – CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.Intuitive Surgical (ISRG) – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.Tenet Healthcare (THC) – Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.Interactive Brokers (IBKR) – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.Edwards Lifesciences (EW) – Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.","news_type":1,"symbols_score_info":{"YMmain":0.9,"MRNA":0.9,".DJI":0.9,"NDAQ":0.9,"NQmain":0.9,"NCLH":0.9,"WBT":0.9,"THC":0.9,"HAL":0.9,"NFLX":0.9,".IXIC":0.9,"ESmain":0.9,"ANTM":0.9,"VZ":0.9,".SPX":0.9,"ASML":0.9}},"isVote":1,"tweetType":1,"viewCount":2061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":602333381,"gmtCreate":1638969966940,"gmtModify":1638969966940,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Meme your mother&nbsp;","listText":"Meme your mother&nbsp;","text":"Meme your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602333381","repostId":"1160989369","repostType":2,"repost":{"id":"1160989369","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890853,"share":"https://www.laohu8.com/m/news/1160989369?lang=zh_CN&edition=full","pubTime":"2021-12-07 23:27","market":"us","language":"en","title":"Meme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160989369","media":"Tiger Newspress","summary":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisit","content":"<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p><p><blockquote>Meme股票在早盘交易中上涨。Vinco Ventures、IronNet、Zomedica、Aterian、Digital World Acquisition、Greenidge Generation、Senseonics、Newegg、AMC和游戏驿站上涨5%至18%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme stocks jumped in morning trading<blockquote>模因股票早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-07 23:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p><p><blockquote>Meme股票在早盘交易中上涨。Vinco Ventures、IronNet、Zomedica、Aterian、Digital World Acquisition、Greenidge Generation、Senseonics、Newegg、AMC和游戏驿站上涨5%至18%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KOSS":"高斯电子","BBIG":"Vinco Ventures, Inc.","EXPR":"Express, Inc.","CLOV":"Clover Health Corp","GREE":"Greenidge Generation Holdings Inc.","OCGN":"Ocugen","GME":"游戏驿站","ATER":"Aterian Inc.","NEGG":"Newegg Comm Inc.","BB":"黑莓","AMC":"AMC院线","BBBY":"Bed Bath & Beyond, Inc.","PHUN":"Phunware, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160989369","content_text":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC and GameStop climbed between 5% and 18%.","news_type":1,"symbols_score_info":{"BB":0.9,"CLOV":0.9,"DWAC":0.9,"EXPR":0.9,"BBBY":0.9,"ATER":0.9,"GREE":0.9,"ZOM":0.9,"MRIN":0.9,"PHUN":0.9,"IRNT":0.9,"AMC":0.9,"NEGG":0.9,"KOSS":0.9,"GME":0.9,"OCGN":0.9,"BBIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606614244,"gmtCreate":1638870615594,"gmtModify":1638870615594,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"I am betting on&nbsp;your mother","listText":"I am betting on&nbsp;your mother","text":"I am betting on your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606614244","repostId":"1159607563","repostType":2,"repost":{"id":"1159607563","kind":"news","pubTimestamp":1638861435,"share":"https://www.laohu8.com/m/news/1159607563?lang=zh_CN&edition=full","pubTime":"2021-12-07 15:17","market":"us","language":"en","title":"Ocugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159607563","media":"InvestorPlace","summary":"Don't go bottom-fishing with OCGN stock even if it's at an enticing support level","content":"<p><div> For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price. Yet, let’s not forget the...</p><p><blockquote><div>对于技术交易者来说，积累生物制药公司Ocugen（纳斯达克股票代码：OCGN）的股票可能很有诱惑力，因为OCGN股票已经跌至看似公平的价格。然而，我们不要忘记...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Investors Are Betting On a Horse Than Can’t Win the Race<blockquote>Ocugen投资者押注于一匹无法赢得比赛的马</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-07 15:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price. Yet, let’s not forget the...</p><p><blockquote><div>对于技术交易者来说，积累生物制药公司Ocugen（纳斯达克股票代码：OCGN）的股票可能很有诱惑力，因为OCGN股票已经跌至看似公平的价格。然而，我们不要忘记...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159607563","content_text":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is known as Covaxin.\nOcugen is co-developing Covaxin with India-based Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring 2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853539585,"gmtCreate":1634823296736,"gmtModify":1634823712607,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Mother fool","listText":"Mother fool","text":"Mother fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853539585","repostId":"1171915283","repostType":2,"repost":{"id":"1171915283","kind":"news","pubTimestamp":1634817585,"share":"https://www.laohu8.com/m/news/1171915283?lang=zh_CN&edition=full","pubTime":"2021-10-21 19:59","market":"us","language":"en","title":"7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171915283","media":"Motley Fool","summary":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so f","content":"<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p><p><blockquote>股票表现之间不存在竞争<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）今年迄今为止。Ocugen的股价飙升约为Novavax的七倍。</blockquote></p><p> Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p><p><blockquote>这是否使Ocugen成为现在购买更明智的疫苗股票？一点也不。以下是Novavax股票比Ocugen更容易选择的七个原因。</blockquote></p><p> 1. A path to EUA in the U.S.</p><p><blockquote>1.美国EUA之路。</blockquote></p><p> Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p><p><blockquote>Ocugen的股价在2021年两次飙升超过750%。但在该公司6月份披露将不再在美国寻求COVID-19疫苗科瓦克辛的紧急使用授权(EUA)后，这一巨大收益大部分消失了。</blockquote></p><p> The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p><p><blockquote>该公司选择在美国获得全面批准后立即获得批准。美国食品药品监督管理局限制了哪些疫苗将在EUA计划下接受审查。然而，到目前为止，Ocugen尚未开始获得FDA全面批准所需的后期临床研究。</blockquote></p><p> Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p><p><blockquote>与此同时，Novavax仍将其COVID-19候选疫苗NVX-CoV2373的美国EUA作为重中之重。该公司在美国申请授权的时间将比预期的要晚。然而，它有可能比Ocugen更早在美国推出。</blockquote></p><p> Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p><p><blockquote>Ocugen仍希望获得科瓦克辛在加授权。但美国是大奖。Novavax现在显然有更好的机会获得这个奖项。</blockquote></p><p> 2. Supply deals already in hand</p><p><blockquote>2.已在手的供应交易</blockquote></p><p> Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p><p><blockquote>一些投资者完全关注COVID-19疫苗的批准或授权流程。然而，如果没有与至少一个国家达成供应协议，任何监管上的胜利都将是空洞的胜利。</blockquote></p><p> Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p><p><blockquote>Ocugen尚未敲定任何供应交易。另一方面，Novavax已经与美国、加拿大、欧盟、澳大利亚、新西兰、日本（通过其合作伙伴，<b>武田</b>）和疫苗联盟Gavi。</blockquote></p><p> 3. Full rights to its COVID-19 vaccine</p><p><blockquote>3.对其COVID-19疫苗的完全权利</blockquote></p><p> Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p><p><blockquote>Ocugen仅在美国和加拿大从Bharat Biotech获得了科瓦克辛的商业化权利。它与Bharat的条款允许该公司保留在这两个市场销售COVID-19疫苗利润的45%。</blockquote></p><p> Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p><p><blockquote>Novavax自行开发了NVX-CoV2373。它保留了疫苗的全部权利，尽管它已经与其他组织合作瞄准了一些市场。</blockquote></p><p> 4. A stronger pipeline</p><p><blockquote>4.更强大的管道</blockquote></p><p> Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p><p><blockquote>除了科瓦克辛之外，Ocugen目前没有任何其他正在进行临床测试的候选产品。该公司曾表示，计划在2021年将实验性基因疗法OCU400推进到两项1/2a期临床试验中，但这些研究尚未开始。</blockquote></p><p> Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p><p><blockquote>Novavax已经报告了候选流感疫苗NanoFlu的3期研究的积极结果。它于9月启动了一项1/2期研究，评估NVX-CoV2373和NanoFlu的组合。该公司还有另外两种处于临床阶段的候选疫苗——呼吸道合胞病毒疫苗ResVax和埃博拉病毒疫苗。</blockquote></p><p> 5. More cash</p><p><blockquote>5.更多现金</blockquote></p><p> Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p><p><blockquote>现金对于临床阶段的生物技术极其重要。如果没有足够的现金，他们可能被迫通过稀释性股票发行来筹集资金，为运营和昂贵的临床试验提供资金。</blockquote></p><p> As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p><p><blockquote>截至2021年6月30日，Ocugen的现金、现金等价物和限制性现金总计1.158亿美元。截至同日，Novavax的现金储备为21亿美元。</blockquote></p><p> 6. More potential near-term catalysts</p><p><blockquote>6.更多潜在的近期催化剂</blockquote></p><p> Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p><p><blockquote>Ocugen实际上只有一个可靠的潜在近期催化剂：它正在等待加拿大卫生部关于科瓦克辛授权的决定。该疫苗在加拿大或美国以外的任何胜利都有利于Bharat，但不利于Ocugen。</blockquote></p><p> What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p><p><blockquote>诺瓦瓦克斯呢？该公司希望尽快赢得印度、印度尼西亚和菲律宾的EUA。Novavax正在等待世界卫生组织将NVX-CoV2373列入紧急使用清单。它还正在向英国、欧洲、澳大利亚、加拿大、新西兰和美国提交监管文件。</blockquote></p><p> 7. A more defensible valuation</p><p><blockquote>7.更合理的估值</blockquote></p><p> Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p><p><blockquote>Ocugen今年迄今为止令人印象深刻的表现在很大程度上源于强烈的在线兴趣和大量股票被卖空的结合。这使得该股成为空头挤压的良好候选者。但该公司的市值超过16亿美元，分析师预计Ocugen明年的收入仅为1.35亿美元左右。</blockquote></p><p> Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p><p><blockquote>不过，如果Novavax获得NVX-CoV2373的授权和批准，它可能很快就会看到大笔资金流入。该公司的市值接近124亿美元。然而，由于预计2022年收入为55亿美元，这一估值比Ocugen的估值更合理。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen<blockquote>Novavax比Ocugen更容易选择的7个原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-21 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p><p><blockquote>股票表现之间不存在竞争<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）今年迄今为止。Ocugen的股价飙升约为Novavax的七倍。</blockquote></p><p> Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p><p><blockquote>这是否使Ocugen成为现在购买更明智的疫苗股票？一点也不。以下是Novavax股票比Ocugen更容易选择的七个原因。</blockquote></p><p> 1. A path to EUA in the U.S.</p><p><blockquote>1.美国EUA之路。</blockquote></p><p> Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p><p><blockquote>Ocugen的股价在2021年两次飙升超过750%。但在该公司6月份披露将不再在美国寻求COVID-19疫苗科瓦克辛的紧急使用授权(EUA)后，这一巨大收益大部分消失了。</blockquote></p><p> The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p><p><blockquote>该公司选择在美国获得全面批准后立即获得批准。美国食品药品监督管理局限制了哪些疫苗将在EUA计划下接受审查。然而，到目前为止，Ocugen尚未开始获得FDA全面批准所需的后期临床研究。</blockquote></p><p> Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p><p><blockquote>与此同时，Novavax仍将其COVID-19候选疫苗NVX-CoV2373的美国EUA作为重中之重。该公司在美国申请授权的时间将比预期的要晚。然而，它有可能比Ocugen更早在美国推出。</blockquote></p><p> Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p><p><blockquote>Ocugen仍希望获得科瓦克辛在加授权。但美国是大奖。Novavax现在显然有更好的机会获得这个奖项。</blockquote></p><p> 2. Supply deals already in hand</p><p><blockquote>2.已在手的供应交易</blockquote></p><p> Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p><p><blockquote>一些投资者完全关注COVID-19疫苗的批准或授权流程。然而，如果没有与至少一个国家达成供应协议，任何监管上的胜利都将是空洞的胜利。</blockquote></p><p> Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p><p><blockquote>Ocugen尚未敲定任何供应交易。另一方面，Novavax已经与美国、加拿大、欧盟、澳大利亚、新西兰、日本（通过其合作伙伴，<b>武田</b>）和疫苗联盟Gavi。</blockquote></p><p> 3. Full rights to its COVID-19 vaccine</p><p><blockquote>3.对其COVID-19疫苗的完全权利</blockquote></p><p> Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p><p><blockquote>Ocugen仅在美国和加拿大从Bharat Biotech获得了科瓦克辛的商业化权利。它与Bharat的条款允许该公司保留在这两个市场销售COVID-19疫苗利润的45%。</blockquote></p><p> Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p><p><blockquote>Novavax自行开发了NVX-CoV2373。它保留了疫苗的全部权利，尽管它已经与其他组织合作瞄准了一些市场。</blockquote></p><p> 4. A stronger pipeline</p><p><blockquote>4.更强大的管道</blockquote></p><p> Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p><p><blockquote>除了科瓦克辛之外，Ocugen目前没有任何其他正在进行临床测试的候选产品。该公司曾表示，计划在2021年将实验性基因疗法OCU400推进到两项1/2a期临床试验中，但这些研究尚未开始。</blockquote></p><p> Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p><p><blockquote>Novavax已经报告了候选流感疫苗NanoFlu的3期研究的积极结果。它于9月启动了一项1/2期研究，评估NVX-CoV2373和NanoFlu的组合。该公司还有另外两种处于临床阶段的候选疫苗——呼吸道合胞病毒疫苗ResVax和埃博拉病毒疫苗。</blockquote></p><p> 5. More cash</p><p><blockquote>5.更多现金</blockquote></p><p> Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p><p><blockquote>现金对于临床阶段的生物技术极其重要。如果没有足够的现金，他们可能被迫通过稀释性股票发行来筹集资金，为运营和昂贵的临床试验提供资金。</blockquote></p><p> As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p><p><blockquote>截至2021年6月30日，Ocugen的现金、现金等价物和限制性现金总计1.158亿美元。截至同日，Novavax的现金储备为21亿美元。</blockquote></p><p> 6. More potential near-term catalysts</p><p><blockquote>6.更多潜在的近期催化剂</blockquote></p><p> Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p><p><blockquote>Ocugen实际上只有一个可靠的潜在近期催化剂：它正在等待加拿大卫生部关于科瓦克辛授权的决定。该疫苗在加拿大或美国以外的任何胜利都有利于Bharat，但不利于Ocugen。</blockquote></p><p> What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p><p><blockquote>诺瓦瓦克斯呢？该公司希望尽快赢得印度、印度尼西亚和菲律宾的EUA。Novavax正在等待世界卫生组织将NVX-CoV2373列入紧急使用清单。它还正在向英国、欧洲、澳大利亚、加拿大、新西兰和美国提交监管文件。</blockquote></p><p> 7. A more defensible valuation</p><p><blockquote>7.更合理的估值</blockquote></p><p> Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p><p><blockquote>Ocugen今年迄今为止令人印象深刻的表现在很大程度上源于强烈的在线兴趣和大量股票被卖空的结合。这使得该股成为空头挤压的良好候选者。但该公司的市值超过16亿美元，分析师预计Ocugen明年的收入仅为1.35亿美元左右。</blockquote></p><p> Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p><p><blockquote>不过，如果Novavax获得NVX-CoV2373的授权和批准，它可能很快就会看到大笔资金流入。该公司的市值接近124亿美元。然而，由于预计2022年收入为55亿美元，这一估值比Ocugen的估值更合理。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171915283","content_text":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes that make Ocugen the smarter vaccine stock to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.\n1. A path to EUA in the U.S.\nOcugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.\nThe company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.\nMeanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.\nOcugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.\n2. Supply deals already in hand\nSome investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.\nOcugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,Takeda), and Gavi, the Vaccine Alliance.\n3. Full rights to its COVID-19 vaccine\nOcugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.\nNovavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.\n4. A stronger pipeline\nOther than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.\nNovavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.\n5. More cash\nCash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.\nAs of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.\n6. More potential near-term catalysts\nOcugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.\nWhat about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.\n7. A more defensible valuation\nOcugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.\nNovavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.","news_type":1,"symbols_score_info":{"OCGN":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":372941567,"gmtCreate":1619171841559,"gmtModify":1634288015707,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Retarded&nbsp;face","listText":"Retarded&nbsp;face","text":"Retarded face","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/372941567","repostId":"1144940040","repostType":4,"isVote":1,"tweetType":1,"viewCount":1633,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378192346,"gmtCreate":1619008614285,"gmtModify":1634289268600,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","listText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","text":"Please talk about Ocugen OCGN. They will be saving the world, together with India.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/378192346","repostId":"1133987686","repostType":4,"repost":{"id":"1133987686","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619007348,"share":"https://www.laohu8.com/m/news/1133987686?lang=zh_CN&edition=full","pubTime":"2021-04-21 20:15","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133987686","media":"Tiger Newspress","summary":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. fu","content":"<p><ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p><blockquote><ul><li>Netflix拖累纳斯达克期货</li></ul><ul><li>10年期国债收益率跌至5周低点后停止涨势</li></ul>美国期货涨跌互现，因为纳斯达克100指数表现不佳，表明从大流行热门股的轮换正在取得进展。美国国债收益率止住了跌至五周低点的下滑。</blockquote></p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨11点，涨幅0.03%，标普500 e-mini下跌0.75点，涨幅0.02%，纳斯达克100 e-mini下跌26.75点，涨幅0.19%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:00</span></p></blockquote></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><blockquote>流媒体服务提供商Netflix在盘前交易中下跌8.5%，此前其报告显示，疫情期间电视节目和电影制作放缓损害了第一季度的订户增长。</blockquote></p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><blockquote><b>Netflix(NFLX)</b>–Netflix在盘前交易中下跌8.5%，尽管其最新季度的营收和利润均超出预期。投资者关注这家视频流媒体巨头弱于预期的用户增长数据。</blockquote></p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><blockquote><b>阿斯麦(ASML)</b>–ASML公布第一季度利润好于预期，该半导体制造设备供应商受益于全球芯片需求激增，盘前股价上涨3.9%。ASML也上调了全年预期。</blockquote></p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><blockquote><b>现代（MRNA）</b>–在与以色列达成2022年新的Covid-19疫苗供应协议后，该制药商股价在盘前交易中上涨0.5%。以色列还可以选择购买旨在治疗特定病毒变种的疫苗。</blockquote></p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><blockquote><b>挪威邮轮公司(NCLH)</b>-高盛将这家邮轮运营商的评级从“中性”上调至“买入”后，挪威股价盘前上涨1.8%。高盛列举了几个积极因素，包括挪威航空的产能增长和与同行相比的低杠杆率。</blockquote></p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><blockquote><b>威瑞森(VZ)</b>-Verizon公布季度收益为每股1.31美元，比预期高出2美分。收入也超出了分析师的预期。Verizon本季度失去的无线用户数量超出了分析师的预期。</blockquote></p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><blockquote><b>韦尔比尔特(WBT)</b>-专业餐饮服务设备制造商Welbilt同意被竞争对手Middleby(MIDD)以隐含价值43亿美元的全股票交易收购，该公司股价在盘前飙升20%。</blockquote></p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><blockquote><b>国歌(ANTM)</b>-这家健康保险公司最近一个季度每股收益7.01美元，比预期高出50美分。收入低于华尔街的预测。由于各种医疗计划的增长和药房福利管理收入的增加，Anthem还上调了全年预期。该股在盘前交易中上涨1.6%。</blockquote></p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><blockquote><b>纳斯达克(NDAQ)</b>–该证券交易所运营商第一季度每股收益1.96美元，比预期高出23美分。收入也高于华尔街的预测。股票和固定收益交易收入两位数增长提振了业绩。纳斯达克还宣布将股息增加10%。</blockquote></p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><blockquote><b>哈里伯顿(HAL)</b>-哈里伯顿股价在盘前上涨1.7%，每股收益超出预期2美分，季度利润为每股19美分。收入也高于预期，这家油田服务公司表示其北美业务继续健康复苏。</blockquote></p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><blockquote><b>贝克休斯(BKR)</b>–这家油田服务公司公布季度收益为每股12美分，比预期高出每股1美分，盘前股价下跌1.4%。收入基本符合预期。受严冬天气影响，利润同比下降40%。</blockquote></p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><blockquote><b>CSX(CSX)</b>-CSX每股下跌2美分，低于预期，季度收益为每股93美分。该铁路运营商的收入高于预期。与大流行相关的中断和更高的燃料成本侵蚀了CSX的利润。CSX在盘前交易中下跌1%。</blockquote></p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><blockquote><b>直觉外科(ISRG)</b>-Intuitive Surgical最近一个季度的每股收益为3.52美元，远高于每股2.63美元的普遍预期。这家手术设备制造商的收入也超出了预期，随着Covid-19大流行的缓解，使用该公司设备的手术数量有所增加。该股在盘前交易中上涨3.9%。</blockquote></p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><blockquote><b>特尼特医疗保健(THC)</b>-Tenet报告季度利润为每股1.30美元，而市场普遍预期为每股72美分。医院运营商的收入略高于预期。特尼特表示，它能够成功应对与大流行和冬季风暴相关的挑战，并给出了乐观的前景。Tenet在盘前交易中上涨2.7%。</blockquote></p><p></p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><blockquote><b>盈透证券(IBKR)</b>-盈透证券每股收益比预期高出7美分，季度收益为每股98美分。交易佣金增长53%，收入远高于预期。该股在盘前交易中上涨2.1%。</blockquote></p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p><p><blockquote><b>爱德华兹生命科学(EW)</b>-爱德华兹股价盘前上涨3.8%，每股收益超出预期7美分，季度利润为每股54美分。收入也高于普遍预期，由于心脏相关手术需求的预期增加，该医疗器械公司还上调了全年预期。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-21 20:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p><blockquote><ul><li>Netflix拖累纳斯达克期货</li></ul><ul><li>10年期国债收益率跌至5周低点后停止涨势</li></ul>美国期货涨跌互现，因为纳斯达克100指数表现不佳，表明从大流行热门股的轮换正在取得进展。美国国债收益率止住了跌至五周低点的下滑。</blockquote></p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p><blockquote>截至美国东部时间上午8:00，道指e-mini上涨11点，涨幅0.03%，标普500 e-mini下跌0.75点，涨幅0.02%，纳斯达克100 e-mini下跌26.75点，涨幅0.19%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:00</span></p></blockquote></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><blockquote>流媒体服务提供商Netflix在盘前交易中下跌8.5%，此前其报告显示，疫情期间电视节目和电影制作放缓损害了第一季度的订户增长。</blockquote></p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><blockquote><b>Netflix(NFLX)</b>–Netflix在盘前交易中下跌8.5%，尽管其最新季度的营收和利润均超出预期。投资者关注这家视频流媒体巨头弱于预期的用户增长数据。</blockquote></p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><blockquote><b>阿斯麦(ASML)</b>–ASML公布第一季度利润好于预期，该半导体制造设备供应商受益于全球芯片需求激增，盘前股价上涨3.9%。ASML也上调了全年预期。</blockquote></p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><blockquote><b>现代（MRNA）</b>–在与以色列达成2022年新的Covid-19疫苗供应协议后，该制药商股价在盘前交易中上涨0.5%。以色列还可以选择购买旨在治疗特定病毒变种的疫苗。</blockquote></p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><blockquote><b>挪威邮轮公司(NCLH)</b>-高盛将这家邮轮运营商的评级从“中性”上调至“买入”后，挪威股价盘前上涨1.8%。高盛列举了几个积极因素，包括挪威航空的产能增长和与同行相比的低杠杆率。</blockquote></p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><blockquote><b>威瑞森(VZ)</b>-Verizon公布季度收益为每股1.31美元，比预期高出2美分。收入也超出了分析师的预期。Verizon本季度失去的无线用户数量超出了分析师的预期。</blockquote></p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><blockquote><b>韦尔比尔特(WBT)</b>-专业餐饮服务设备制造商Welbilt同意被竞争对手Middleby(MIDD)以隐含价值43亿美元的全股票交易收购，该公司股价在盘前飙升20%。</blockquote></p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><blockquote><b>国歌(ANTM)</b>-这家健康保险公司最近一个季度每股收益7.01美元，比预期高出50美分。收入低于华尔街的预测。由于各种医疗计划的增长和药房福利管理收入的增加，Anthem还上调了全年预期。该股在盘前交易中上涨1.6%。</blockquote></p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><blockquote><b>纳斯达克(NDAQ)</b>–该证券交易所运营商第一季度每股收益1.96美元，比预期高出23美分。收入也高于华尔街的预测。股票和固定收益交易收入两位数增长提振了业绩。纳斯达克还宣布将股息增加10%。</blockquote></p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><blockquote><b>哈里伯顿(HAL)</b>-哈里伯顿股价在盘前上涨1.7%，每股收益超出预期2美分，季度利润为每股19美分。收入也高于预期，这家油田服务公司表示其北美业务继续健康复苏。</blockquote></p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><blockquote><b>贝克休斯(BKR)</b>–这家油田服务公司公布季度收益为每股12美分，比预期高出每股1美分，盘前股价下跌1.4%。收入基本符合预期。受严冬天气影响，利润同比下降40%。</blockquote></p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><blockquote><b>CSX(CSX)</b>-CSX每股下跌2美分，低于预期，季度收益为每股93美分。该铁路运营商的收入高于预期。与大流行相关的中断和更高的燃料成本侵蚀了CSX的利润。CSX在盘前交易中下跌1%。</blockquote></p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><blockquote><b>直觉外科(ISRG)</b>-Intuitive Surgical最近一个季度的每股收益为3.52美元，远高于每股2.63美元的普遍预期。这家手术设备制造商的收入也超出了预期，随着Covid-19大流行的缓解，使用该公司设备的手术数量有所增加。该股在盘前交易中上涨3.9%。</blockquote></p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><blockquote><b>特尼特医疗保健(THC)</b>-Tenet报告季度利润为每股1.30美元，而市场普遍预期为每股72美分。医院运营商的收入略高于预期。特尼特表示，它能够成功应对与大流行和冬季风暴相关的挑战，并给出了乐观的前景。Tenet在盘前交易中上涨2.7%。</blockquote></p><p></p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><blockquote><b>盈透证券(IBKR)</b>-盈透证券每股收益比预期高出7美分，季度收益为每股98美分。交易佣金增长53%，收入远高于预期。该股在盘前交易中上涨2.1%。</blockquote></p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p><p><blockquote><b>爱德华兹生命科学(EW)</b>-爱德华兹股价盘前上涨3.8%，每股收益超出预期7美分，季度利润为每股54美分。收入也高于普遍预期，由于心脏相关手术需求的预期增加，该医疗器械公司还上调了全年预期。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NCLH":"挪威邮轮","HAL":"哈里伯顿","NFLX":"奈飞","THC":"泰尼特",".IXIC":"NASDAQ Composite","VZ":"Verizon Comms",".SPX":"S&P 500 Index","WBT":" Manitowoc Food Service",".DJI":"道琼斯","MRNA":"Moderna, Inc.","ASML":"阿斯麦","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133987686","content_text":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.*Source From Tiger Trade, EST 08:00Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.Stocks making the biggest moves in the premarket:Netflix (NFLX) – Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.ASML (ASML) – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.Moderna (MRNA) – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.Norwegian Cruise Line (NCLH) – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.Verizon (VZ) – Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.Welbilt (WBT) – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.Anthem (ANTM) – The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.Nasdaq (NDAQ) – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.Halliburton (HAL) – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.Baker Hughes (BKR) – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.CSX (CSX) – CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.Intuitive Surgical (ISRG) – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.Tenet Healthcare (THC) – Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.Interactive Brokers (IBKR) – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.Edwards Lifesciences (EW) – Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.","news_type":1,"symbols_score_info":{"YMmain":0.9,"MRNA":0.9,".DJI":0.9,"NDAQ":0.9,"NQmain":0.9,"NCLH":0.9,"WBT":0.9,"THC":0.9,"HAL":0.9,"NFLX":0.9,".IXIC":0.9,"ESmain":0.9,"ANTM":0.9,"VZ":0.9,".SPX":0.9,"ASML":0.9}},"isVote":1,"tweetType":1,"viewCount":2061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}